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The half-hfc el" ubiqmnone-9 in var~oa~ rat t~zsue~ was determined Rat~ were in.leered mtrapentoneally with (~H]mevalonate and the decay of 
radioaetivlty incorporated into ablqttinone-9 was followed using ~cverse-phase HPLC. Tile halfhfe varied between 49 h (te~tm)and 125 h (k~d~ey) 
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1. INTRODUCTION 
Ubiquinone has a broad distribution in animal tissues 
and the amount present on a weight basis in different 
tissues varies to only a limited extent [1-3]. Upon 
subfraetionati.on this compound is recovered in all 
membranes, being particularly enriched in Golgi, lyso- 
somal and inner mitochondrial membranes [4]. 
The terminal portion of ubiquinone biosynthesis oc- 
curs exclusively in Golgi vesicles and it thus appears 
that this lipid is transported from this location to the 
various other organelles through the cytoplasm [5]. The 
major established function of ubiquinone is its partici- 
pation in the mitochondrial respiratory chain as a redox 
component, but this function does ~.ot explain its pres- 
ence in most other membranes [6]. Increasing evidence 
obtained in recent years indicates that ubiquinone in the 
reduced form plays an important role as a cellular anti- 
oxidant [7,8]. Available reports uggest that for quench- 
ing free radicals and reactive oxygen species, cells prefer 
ubiquinol to ~-tocopherol [9]. 
The level of ubiquinone is altered considerably in 
connection with various physiological and pathophysi- 
ologieal conditions, indicating the importance of this 
lipid in cellular life [10,1 I]. Both in humans and in rat 
the amount of ubiquinone in most tissues increases after 
birth, while later in life this amoun~ decreases [12]. A 
high-cholesterol diet lowers the amount of this compo- 
nent in liver, whereas treatment with clofibrate, N-nitro- 
sodiethylamine or, in particular, di(2-ethylhexyl)phtal- 
ate increases its cellular concentrations [13]. The level 
of ubiquinone in hyperplzstic noduli is increased, but in 
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tumors only half of the original content of this lipid 
remains [14]. Human studies have demonstrated the 
presence of low ubiquinone concentrations in cardio- 
myopathies and various muscle diseases [15,16]. 
In rive and in vitro studies have demonstrated that 
biosynthesis of ubiquinone occurs in all tissues, but the 
rates of biosynthesis and breakdown of this lipid in 
different issues are not yet known. Uptake of dietary 
ubiquinone occurs only to a limited extent and, conse- 
quently, most of this lipid is provided by de nero syn- 
thesis. The high rate of its synthesis i an indirect indica- 
tion for a well functioning mechanism for breakdown. 
The aim of the present study was to investigate the 
half-life of ubiquinone and examine possible variations 
in it~ turnover in various types of tissues. This was 
achieved by monitoring the decay of radioactivity incor- 
porated into this lipid from a labeled precursor. 
2. MATERIALS AND METHODS 
Male Sprague-Dawley rata weighing 180 8 at the beginning or tile 
experiment were ubed in all cases. The~e animals were injected in- 
t~apcntoneally with 1 mCi RS-5-[alq]mevalonolactone (30 C~/mmo]) 
dl~solved m 0.9% Nat l .  Synthesl~ of labeled mevalonolactone wa~ 
performed as de~erib~l earlier [17]. 
T~ssues were nomogenized using a Turrax tdtra blender. The homo- 
gcnate5 were ~upplemented with 4 ,t~g ubiqumone-6 (Slglntt) a5 an 
internal standard and thereafter extracted twice witla chloro- 
lorrn:methanol, 2:1, wit_heat alkaline hydrolysis. After washing this 
extract w~tll the theoretical upper phaBe (chloroform:methanol.water, 
3.48:47) the chlorol'orm fraction was placed onto a filica column to 
remove charged hp~ds. The chloroform el'lluent wa~ collected and the 
~olven! evaporated. The residue w,t~ then d~n~qolv,~d m 30,ttl n-he~ane 
and analyzed by HPLC using a Hewlett Packard hyper~il ODS (Cta) 
3/.tnl reverbe-pha~e column. A linear gradient was used from the m~Iml 
2-propanol:methanol:hexane, 40.60:5, m pump ~y~tem A to hexane.2- 
~ropanol, 70.30, m pump system B, w,th a flow rate of 1.5 ml/mm and 
a prosram rune of 35 mla. The nbaorpt~ua tJi" th~ eluate ~,tn mumto~ ed 
at 27.5 nm and radioactivity was meazared ufin/3 a radio flow detector 
(RadmmatJ¢, Tampa, FL). 
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3. RESULTS AND DISCUSSION 
Effective labeling of isoprenoid lipids is difficult to 
achieve using initial precursors, uch as acetate, because 
of the man~ metabolic pathways which utilize these 
compounds. [~H]Mevalonate is employed primarily tbr 
studying the biosynthesis of cholesterol, but, in addi- 
tion, labeled mevalonate is also incorporated into iso- 
prenoids covalently bound to proteins, into dolichols 
and into ubiquinone [18]. 
It is quite important in the present ype of study to 
attain complete xtraction and eft'ective purification of 
ubiquinone by HPLC. Quantitative xtraction is possi- 
ble even without alkaline hydrolysis and ubiquinone 
may subsequently be isolated by reverse-phase HPLC. 
The major form of this lipid in rat tissues was found to 
contain 9 isoprene residues, but in certain tissues mall 
amounts of ubiquinone-10 were also present (Fi~. 1). 
In this study the labeling behavior of ubiquinone-9 
was monitored. The half-lives of ubiquinone-9 isolated 
from various tissues were investigated by following the 
decay in radioactive labeling after intraperitoneal injec- 
tion of [3H]mevalonate. Fig. 2 illustrates the pattern 
obtained with heart tissue, as an example. The initial 
time-point was chosen as 23 h after the intraperitoneal 
injection. After this period free [~H]mevalouate could 
no longer be detected in the cytoplasm ofvarious tissues 
(not shown). Using a semilogarithmic plot, the decay in 
radioactivity was followed tbr 160 h; during this period 
the decay was tbund to be linear. 
The amount of ubiquinone-9 in tissue varies between 
20 and 170 pg/g wet weight, the lowest values being 
found for testis, spleen and thymus and the highest for 
heart, liver and kidney (Table 1). The half-life of this 
lipid displays quite limited variation among the tissues 
measured. In heart° muscle, testis, thyroid~ intestine, 
colon and spleen the tl,,. values were between 50 and 60 
h, while in stomach, liver and pancreas the correspond- 
ing values were between 70 and 90 h. The half-li,,'~s in 
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Fig. l. S~paration of lipids extracted from rat heart by HPLC 
Cholesterol and squalene were ioenufied u~ing ~tandard~ wl,~.h cu- 
re,grated w~th the radioacuve p aks. Dashed hn~, ab~orbanc~ at 275 
am; ~olid line, radioactivity in dpm Q-6, ubiquinone.6 (internal stun. 
data); Q-9 and -10, ublquinone-9 and -10. 
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F~$ 2 Decay of specific radioacuvJty m h~trt ubiquinone.9. Ubtqui- 
none-9 was l~olated from heart homogenate at vanou~ timc-pomts 
after intraperitoneal inj~tlon of [~H]mcvalonate, nd tt~ level of rath- 
oachve labeling determined. The values are the means of six expert- 
meres + S.D, 
thymus and kidney were somewhat longer i.e. 104 and 
125 h, respectively. 
The halt-life values obtained in these experiments 
were most probably not affected by re-util~ition of the 
radioactive label. In contrast to amino acids the mevalo- 
note molecule is modified on its way to appearing in 
isoprenotd lipids. There are no data available concern- 
ing the route of breakdown of isoprenoid lipids in ani- 
mal tissues. However, even if acetate appears as a final 
end-product of this catabolic pathway, utilization of 
this labeled precursor lbr synthesis of ubiquinone is 
probably insignificant. Nor can the relatively long half- 
life of ubtquinone in kidney be explained by accumula. 
tion of radioactive precursor in this organ, since the 
mevalonate pool in kidney is small [19]. 
The half-lives of  phespholipids are around 100 h, of 
cholesterol 150 h and of dolichol 65-140 h in rat liver 
[20,21]. Thus, ubiquinone demonstrates a similar range 
Table 1 
Amount~ and half-life of ubiquinooe-9 m various rat tibnues 
]'issue Amount V~g/g wet weight) Half-lilk (h) 
Liver 171 _+ 11.3 79 
Heart 162 ± 102 59 
Kidney 133 -+ 7.9 125 
Stomach 6J.4 ± 4.7 72 
Thyro,d 52.6 +_ 6.1 49 
Colon 46.5 + 3.1 54 
Muscle 46.2 _+ 3.8 50 
Intestine 40.1 + 1.9 54 
Pancreas 32.0 + 2.2 94 
Testis 23.6 _+ 1.4 50 
Thytaus 21.7 :t: 1.8 104 
Spleen 20.3 ± 2 0 64 
l mC1 .~u~ . . . . . . . . . . . .  a~ :nj..~,~A ;n,~l~i,~n..all y into the rol'~ and L • a ja A~, ,w~l~l i .a ,v .  t l  ~ , . ,  ~ . . . . . . . . . . . . . . . .  
alter  var ious  t ime per iods tissues were extracted and the Sl)~ific la- 
oehng of ubiqmnone-9 determined by HPLC. The values are the 
means + S.D of six experiments 
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or even somewhat shorter half-life. The rate of turnover 
of ubiquinone in individual tissues is el" considerable 
interest, l:~¢ause their supply is provided mainly or ex- 
clusively by endogenous metabolism and is not influ- 
enced by dietary or circulatory levels of ubiquinone, in 
contrast to cholesterol. 
The small amount of ubiquinone present in blood is 
not involved in the redistribution, but probably has a 
specific function, such as preventing oxidation of LDL 
cholesterol [9]. This antioxidant function of ubiquinone 
makes it particularly important to determine both the 
amounts and the turnover of this lipid in various tissues. 
Another important factor in this context is the capacity 
of each tissue to maintain ubiquinone in the reduced 
form necessary for its antioxidant action. 
The amounts of ubiquiaon¢ in intracellular mem- 
branes varies, and both organellar and cellular levels 
vary widely in connection with different physiological 
and pathophysiological conditions, Because of its sig- 
nificance for cellular function it will be of importance 
in the future to study the regulation of the biosynthesis 
and breakdown of ubiquinone at different locations. 
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